Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope. 

Multiple medical devices used during cardiopulmonary bypass and extracorporeal membrane oxygenation procedures have been voluntarily recalled due to issues with their packaging.

The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death.

Findings from the SOLVE-CRT study were presented to attendees at Heart Rhythm 2023. "Our results showed the study was safe, effective and feasible," Singh said. 

The drug, which should be available by the end of June, will be marketed under the name Inpefa.

Researchers used multiple AI models to evaluate EHR data from more than 322,000 heart failure patients. By identifying these subtypes, the group thinks clinicians could perform better risk assessments and make more informed treatment decisions. 

Bruce Wilkoff, MD, director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, said the new device could be "an important advancement for heart failure patients."

The FDA has previously approved the SGLT2 inhibitor in patients with HFrEF, but not HFmrEF or HFpEF